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Background: The COVID-19 pandemic has worsened the pain and suffering of chronic pain
patients due to stoppage of “elective” interventional pain management and office visits across the
United States. The reopening of America and restarting of interventional techniques and elective
surgical procedures has started. Unfortunately, with resurgence in some states, restrictions are
once again being imposed. In addition, even during the Phase II and III of reopening, chronic pain
patients and interventional pain physicians have faced difficulties because of the priority selection
of elective surgical procedures.
Chronic pain patients require high intensity care, specifically during a pandemic such as COVID-19.
Consequently, it has become necessary to provide guidance for triaging interventional pain
procedures, or related elective surgery restrictions during a pandemic.
Objectives: The aim of these guidelines is to provide education and guidance for physicians,
healthcare administrators, the public and patients during the COVID-19 pandemic. Our goal is
to restore the opportunity to receive appropriate care for our patients who may benefit from
interventional techniques.
Methods: The American Society of Interventional Pain Physicians (ASIPP) has created the COVID-19
Task Force in order to provide guidance for triaging interventional pain procedures or related
elective surgery restrictions to provide appropriate access to interventional pain management (IPM)
procedures in par with other elective surgical procedures.
In developing the guidance, trustworthy standards and appropriate disclosures of conflicts
of interest were applied with a section of a panel of experts from various regions, specialties,
types of practices (private practice, community hospital and academic institutes) and groups. The
literature pertaining to all aspects of COVID-19, specifically related to epidemiology, risk factors,
complications, morbidity and mortality, and literature related to risk mitigation and stratification
was reviewed. The evidence -- informed with the incorporation of the best available research and
practice knowledge was utilized, instead of a simplified evidence-based approach. Consequently,
these guidelines are considered evidence-informed with the incorporation of the best available
research and practice knowledge.
Results: The Task Force defined the medical urgency of a case and developed an IPM acuity scale
for elective IPM procedures with 3 tiers. These included emergent, urgent, and elective procedures.
Examples of emergent and urgent procedures included new onset or exacerbation of complex
regional pain syndrome (CRPS), acute trauma or acute exacerbation of degenerative or neurological
disease resulting in impaired mobility and inability to perform activities of daily living. Examples
include painful rib fractures affecting oxygenation and post-dural puncture headaches limiting the
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ability to sit upright, stand and walk. In addition, urgent procedures include procedures to treat any severe or debilitating disease
that prevents the patient from carrying out activities of daily living. Elective procedures were considered as any condition that is
stable and can be safely managed with alternatives.
Limitations: COVID-19 continues to be an ongoing pandemic. When these recommendations were developed, different stages
of reopening based on geographical regulations were in process. The pandemic continues to be dynamic creating every changing
evidence-based guidance. Consequently, we provided evidence-informed guidance.
Conclusion: The COVID-19 pandemic has created unprecedented challenges in IPM creating needless suffering for pain patients.
Many IPM procedures cannot be indefinitely postponed without adverse consequences. Chronic pain exacerbations are associated
with marked functional declines and risks with alternative treatment modalities. They must be treated with the concern that they
deserve. Clinicians must assess patients, local healthcare resources, and weigh the risks and benefits of a procedure against the
risks of suffering from disabling pain and exposure to the COVID-19 virus.
Key words: Coronavirus, COVID-19, interventional pain management, COVID risk factors, elective surgeries, interventional
techniques, chronic pain, immunosuppression
Pain Physician 2020: 23:S183-S204

1.0 Introduction
COVID-19 has made a dramatic impact on the
economy, society and healthcare, particularly in the
interventional pain management (IPM) community.
At the height of the COVID-19 pandemic, elective interventional techniques and new patient visits were
eliminated. This resulted in a significant stress placed
upon interventional pain physicians and their practices,
exacerbating burnout (1). A survey conducted by American Society of Interventional Pain Physicians (ASIPP)
revealed the devastating effects of COVID-19 on IPM,
with 98% of the practicing physicians being affected,
54% with new burnout secondary to COVID-19, 55%
attempting to retire from medical practice, 91% affected financially, 66% with a negative outlook of the
future, 73% stressed due to electronic medical records,
67% stressed due to in-house billing, and, finally, 80%
of the physicians performing interventional techniques
(1). Thus, the COVID-19 pandemic has created unprecedented challenges to society-in-general and the health
care system in-particular.
As the lockdown progressed, economic and political pressure surfaced to relax “shelter-in-place,” public
health orders for multiple industries including health
care (2). However, during the lockdown and even with
the phased-in re-opening there have been multiple
practices of the priority-based scheduling interventional pain procedures may have been delayed. In the
United States, a prerequisite for health care facilities
to return to interventional pain procedures, is robust
testing for active infection for at-risk health care professionals, and risk stratification (3,4). With prioritiza-
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tion as criteria, health care facilities are opening, IPM
physicians have not been able to perform their cases at
the same pace as other specialties.

1.1 Impact of Chronic Pain and COVID-19
The impact of chronic pain on society is not only
enormous, but also disproportionate to any other
condition in causing disability and economic toll (5-12).
Among the conditions treated by interventional pain
physicians, chronic persistent spinal pain lasting longer
than one-year is reported in 25% to 60% of all patients
(5-7). Freburger et al (11) in an assessment of the rising
prevalence of chronic low back pain from 1992 to 2006,
showed that the prevalence of chronic, impairing low
back pain rose significantly over the 14-year interval
from 3.9% in 1992 to 10.2% in 2006. Blyth et al (12)
assessed the global burden of musculoskeletal pain and
identified key gaps in the understanding of musculoskeletal pain. Health care expenditures have been escalating over the years with estimates of US health care
spending reaching $3.66 trillion in 2018. Further, health
care expenditures were already expected to continue to
grow at a rate of 5.5% from 2018 to 2027 (13). In 2018,
the cost of health care per capita in the United States
was $11,212, which is expected to increase in 2019 to
$12,194, without including the impact of COVID-19.
Specific to IPM, Dielman et al (8) performed 2 studies
estimating health care spending in the United States for
various conditions. For low back pain they estimated a
spending of a total of $183 billion, with $87.6 billion in
low back and neck pain and on musculoskeletal disorders of $95.5 billion in 2013. However, estimates for in
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2016 showed health care spending increasing from an
estimated $1.5 trillion in 1996 or $5,259 per person to
an estimated $3.1 trillion and per person cost of $9,655
(8). Further, they also showed that for musculoskeletal
disorders spending was second highest with $264.3 billion in 2016 compared to $183 billion in 2013, with a
44.4% increase (8).
Over the years, exploding health care costs have
been identified for management of spinal pain and
chronic pain, including over-the-counter medications
all the way up to complex surgical fusions. However,
in recent years, the utilization of interventional techniques, as well as opioid therapy has shown a flattening of utilization of most modalities even though
there are some modalities with increases and even a
true decline for some services. Ironically, the utilization
of opioids, as well as interventional techniques simultaneously started declining, indicating various issues
related to control of all types of health care modalities
instead of improving non-opioid care (5-7,14-25). A
recent analysis of the growth of utilization of interventional techniques in managing chronic pain in the
Medicare population (14) showed an overall decline in
utilization from 2009 to 2018 of 6.7%, with an annual
decline of 0.8% per 100,000 fee-for-service Medicare
population. Total opioid prescriptions, morphine
milligram equivalents (MME) per person, and opioidrelated deaths have declined substantially (23). Now,
prescription-related opioid deaths at 14,975 in 2018 is
equivalent to deaths of heroin of 14,996 and cocaine
of 14,666. Further, the number of opioid prescriptions
reduced from 251.8 million in 2013 to 168.8 million in
2018. The major issue has been the multitude of other
synthetic narcotics such as fentanyl with total deaths in
2018 of 31,335 (15,22).
Chronic pain is disabling; however, if left untreated,
it can also have serious consequences, the extent of
which may not yet be fully appreciated. It has been
shown that patients with chronic pain who cannot get
appropriate treatment reported that pain interferes
with their basic function, with 50% reported that it
leads to feelings of depression, while 35% reported suicidal ideation (26). This study also reported significant
changes in pain intensity levels, emotional suffering
and disability in pain patients with a wait time of 3
months (26).

1.2 Impact of Delayed Treatment
The inability to consult with an interventional pain
specialist may lead some pain patients to seek out alter-
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nate and possibly inappropriate or harmful treatments
such as elevated doses of nonsteroidal anti-inflammatory drugs (NSAIDs), illicit drugs and escalating opioid
use (27). The COVID-19 pandemic has disrupted pain
care and life as we are accustomed to living across the
globe. In an effort to prevent patients and staff from
being infected with COVID-19 and to divert valuable
healthcare resources to potentially fatal cases of the
COVID-19 infection, elective, routine, and non-urgent
care were halted in secondary and tertiary centers and
special protocols were introduced for primary care,
long-term residential care, hospices, and other settings
(27). However, many patients with chronic pain or at
risk for developing chronic pain conditions were also
those at high risk for COVID-19: older patients, those
with chronic underlying diseases, and those with limited access to healthcare (27). Thus, the individuals who
were most likely to suffer from their chronic pain and
needed treatment were also most likely to be asked to
avoid in-person clinical visits and defer their interventional pain procedures to protect them from possible
viral transmission and preserve resources.
Since pain is the reason for 45% of visits to emergency departments (28), the influx of pain patients
to emergency departments has overwhelmed some
hospitals, ramped up the need for personal protective
equipment (PPE) independent of the COVID-19 units,
and exposed healthcare professionals to the risk of
treating patients with unknown COVID status. Thus,
the treatment of pain is vital to the patient’s health.
An individual with an acute lumbosacral radiculopathy
may be incapacitated as well as treated with escalating
doses of opioids, oral steroids or even surgery although
such a condition could and would likely be treated with
a common intervention such as an epidural injection.
The pain of an individual with a new onset or exacerbation of CRPS of the upper or lower extremities may
be best treated with a single sympathetic block as opposed to alternative treatment options that may not
or have not been as effective. Chronic pain can suppress the immune system, which can adversely impact
survival in certain populations, such as cancer pain
patients (29). Patients with intrathecal drug infusion
systems may suffer distressing or life-threatening withdrawal symptoms, not to mention painful symptoms
if the pump cannot be refilled on time. In addition,
the pump batteries may die leading to the need for
replacement, which is costly. The full consequences of
COVID-19 will likely not be fully assessable until the
end of the pandemic.
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1.3 Consequences of Inadequate Treatment
In many patients, the only option is continuing
opioids with telehealth follow-up visits, although
initiation of opioids or evaluation of new patients
is not recommended. Escalation of opioid doses is
also crucial considering multiple available guidelines
and recommendations, even though these have been
relaxed to a great extent during the pandemic (30).
However, opioids regulate the immune system in
several aspects. It is known that the activation of opioid receptors leads to a reduction in the number of
macrophages, a decrease in phagocytic activity and
accelerated apoptosis. Consequently, pain as well as
opioids both have significant effects on the immune
system, subjecting the patients to further reductions
in immunity and increasing the risk for infections and
delayed recovery.
There have been global, dynamic challenges faced
by healthcare systems to the evolving breakout of COVID-19 that have resulted in elective surgery bans with
no pre-determined end in sight. Despite the emergent
and urgent need of many Americans for continuous
pain care, essential IPM procedures have not been
discussed in the same context as other forms of pain
care, for example, treatment of patients on chronic
opioid therapy. Nor has IPM been described in the same
manner as for other surgical procedures wherein their
acuity, functional impact and disease progression was
assessed.

1.4 State of Guidance
The Centers for Disease Control and Prevention
(CDC) have issued a framework for the care of nonCOVID-19 patients during the pandemic based on a matrix of the risk of harm to the patient balanced against
the risk of harm to the community (31,32). For example,
strokes and heart attacks should be addressed immediately, although care may in some cases be diverted to
a facility less impacted by the pandemic, while physical
therapy (even if it may result in patient harm) should
be delivered remotely if possible and only in person if
there is no risk to the community. Elective procedures
that can be delayed without risk to the patient should
be postponed. This guidance must be individualized for
certain specific cases, for example, in patients with serious underlying diseases or in those with no access to
telehealth options (32).
Despite the tremendous burden that chronic pain
represents to American citizens as well as national
healthcare and the fact that many chronic pain patients
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require continuous care that is especially vital during
times of crisis, there is no guidance on how to prioritize
IPM for these patients in times of dynamic and complicated risk-benefit analysis. Delaying interventional
pain treatments for the treatment of severe acute pain
or acute or chronic pain exacerbations risks devastating
functional impairments that predisposes the patient
to further morbidities, unnecessary surgery or even
mortality.
Multiple guidelines have been published in the
past by various organizations (33-35). Shah et al (3) addressed the risk stratification during COVID-19 for return to interventional pain practices; however, thus far
the role of interventional techniques during the pandemic or resurgence has otherwise not been addressed.
Consequently, chronic pain patients may continue to
suffer without appropriate treatment.
Thus, overlooking medically necessary and indicated care for chronic pain patients can have negative
impacts on health, well-being, emotional stability,
function, and quality of life (27-29,36). Consequently,
pain specialists must balance the needs for pain control
against reasonable concern and precautions related to
coronavirus and the COVID-19 pandemic. Membership
has requested ASIPP to frame guidelines determining
the status of interventional pain procedures based on
their need as elective emergent or urgent. The contextual, tiered framework has been advanced by the Centers for Medicare and Medicaid Services (CMS) in broad
terms to help differentiate low, intermediate, and
high-acuity treatments or services (31,32). In addition,
multiple organizations also have established guidance
for their own specialties (33-35,37,38). Further, multiple
states have utilized stricter guidelines or the guidelines
developed by specialty societies.
Multiple guidelines have been published by
ASIPP in performing various types of interventional
techniques, regenerative medicine, opioids in chronic
non-cancer pain, antithrombotic therapy, sedation, and
facet joint interventions (3,5-7). More recently, pertinent to the subject of the COVID-19 pandemic, ASIPP
has developed evidence-informed risk mitigation and
stratification guidelines during COVID-19 for return to
interventional pain practice. Thus, ASIPP has been at
the forefront of guideline development for the safe
and responsible use of interventional techniques and
opioids (3,5-7). Consequently, to better serve chronic
pain patients, ASIPP established a COVID-19 Task Force
to develop triaging interventional pain procedures or
related elective surgery restrictions.
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2.0 Methods
Chronic pain is defined as a complex and multifactorial disease process with numerous treatment modalities applied in the management of the problem. Additionally, the growing social, economic and COVID-19
pandemic costs have created a huge influence on medical decision making. While interventional techniques
and opioids are the mainstays of treatment, there are
multiple other adjuvant modalities being provided for
the management of chronic pain by interventional pain
physicians.

2.1 Rationale

IPM has been defined as the discipline of medicine
devoted to the diagnosis and treatment of painrelated disorders principally with the application
of interventional techniques in managing
subacute, chronic, persistent, and intractable pain,
independently or in conjunction with other modalities
of treatment ( www.cms.hhs.gov/transmittals/
Downloads/r1779b3.pdf Accessed 5/28/2020). IPM
techniques have been defined as minimally invasive
procedures including percutaneous precision
needle placement of drugs in targeted areas or
ablation of targeted nerves; surgical techniques
such as laser and endoscopic discectomy; and the
placement of intrathecal infusion pumps and spinal
cord stimulators for the diagnosis and management
of chronic, persistent, or intractable pain (
http://medpac.gov/docs/default-source/reports/
december-2001-report-to-the-congress-payingfor-interventional-pain-services-in-ambulatorysettings.pdf?sfvrsn=0 Accessed 5/28/2020).
2.2 Objectives:
The ASIPP COVID-19 Task Force was established
to develop guidance for triaging interventional pain
procedures or related elective surgery restrictions and
to provide a context and strategy for elective interventional procedures and interventional techniques including surgical procedures related to chronic pain. Fundamental to this task are the overarching considerations
of increasing risk without treatment, risk stratification,
and development of safe strategies to develop guidance for triaging interventional pain procedures during
COVID-19 or related elective surgery restrictions. Thus,
development of guidance involves reducing harms to
patients, health care professionals, and the health care
system, and improving quality of care with pain relief
to improve functional status. Thus, identification of
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these factors is very important in development of the
guidelines and taking into account the impact of COVID
on patient population, drug therapy, lack of treatment,
resource utilization, and adverse effects of elective
surgery restrictions on IPM practices, defining medical
urgency of a case, developing IPM acuity scale, and forwarding those recommendations to the membership.
The guidance is not standard of care. Clinicians
must base their decisions on an assessment of individual
risks versus benefits and understand that, ultimately,
these recommendations are dynamic and situational.
As more evidence and understanding of COVID-19
pandemic emerges, more precise recommendations
may follow. In addition, it is crucial to understand that
recommendations made here may or may not be appropriate for every setting and location. Thus, it is crucial
to follow local state and federal regulations and take
an individualized approach.
To perform urgent and emergent procedures, it is
important to stratify or rank patients for their relative
risk of contracting COVID-19 or having a poor outcome
in the event of an infection. A risk stratification scoring
system has been developed to provide a rapid objective
assessment of individual patients, as shown in Fig. 1 and
Table 1.

2.3 Adherence to Trustworthy Standards
In preparation of these guidelines for triaging
interventional pain procedures during the COVID-19
pandemic for return to interventional pain practice, the
standards from the Institute of Medicine (IOM) and the
National Guideline Clearinghouse Extent Adherence to
Trustworthy Standards (NEATS) were followed (39-41).
The NEATS instrument was developed and tested as
a tool to be used by the trained staff at the Agency
for Healthcare Research and Quality (AHRQ) National
Guideline Clearinghouse to provide assessment focused
on adherence.

2.3.1 Disclosure of Guideline Funding Source
Comprehensive evidence-informed guidelines
for risk mitigation/stratification during COVID-19 for
return to interventional pain practice were commissioned, prepared, edited, and endorsed by ASIPP without external funding.

2.3.2 Disclosure and Management of Financial
Conflicts of Interests
Potential conflicts of interest for all panel members within the last 5 years were evaluated prior to
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Fig. 1. COVID-ARMS flow chart to mitigate risks of COVID-19 morbidity during interventional pain encounters.

Adapted with permission: Shah S, Diwan S, Soin A, et al. Evidence-informed risk mitigation and stratification during COVID-19 for return
to interventional pain practice: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2020; 23:S161-S182 (3).

the finalizing of these guidelines. Conflicts of interests
extended beyond financial relationships, including personal experience, practice patterns, academic interests,
and promotions. The panel members with potential
conflicts were recused from discussion or preparation
of the guidelines in which they had conflicts of interest,
and these members agreed not to discuss any aspect of
a given guideline with the related industry before data
publication.

2.3.3 Composition of Guideline Development
Group
A panel of experts in interventional techniques,
opioid therapy and administrative expertise from
various medical fields, convened by ASIPP, reviewed the
evidence and formulated recommendations for triaging interventional pain procedures during COVID-19
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for return to interventional pain practice. Overall, the
panel provided a broad representation of academic and
non-academic clinical practitioners with interest and
expertise in IPM.

2.4 Evidence Review
These guidelines were developed utilizing consensus among the panel members after they had
reviewed all published literature concerning the use
and safety of interventional techniques during and
after the COVID-19 pandemic. The recommendations
have been developed using the principles of best
evidence synthesis developed by the Cochrane Review,
incorporating multiple guidelines modified by ASIPP
(42). In this manuscript, due to the lack of randomized controlled trials or even observational studies
related to IPM and COVID-19, and due to the nature
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Table 1. COVID-ARMS risk stratification of patients presenting for interventional pain procedures for decreasing morbidity of
COVID-19 (points appear in brackets).

If Patient Residence status is Nursing Home or Assisted Living Facility or Incarceration during the past
30 days, consider as HIGH-RISK Patient. If not, follow below table for risk stratification.
Risk Factor
Age (years)
Pulmonary

Low Risk

Moderate Risk

45-64 years
[1]

65-74 years
[2]

≥ 75 years
[3]

None
[0]

Mild intermittent asthma
[2]

Chronic lung condition, i.e., moderate to severe
asthma, COPD
[3]

None
[0]

HTN or CAD
[2]

HTN + CAD
HTN + CHF
HTN + CAD + CHF
CHF alone
[3]

BMI 24.9-29.9
[1]

BMI 30.0-39.9
[2]

BMI > = 40
[3]

5.8-6.49 or
100-120 mg/dl
[1]

6.5-8.49 or
120-160 mg/dl
[2]

> = 8.5 or
>160 mg/dl
[3]

None
[0]

Acute or chronic renal
insufficiency
[2]

Chronic renal insufficiency on dialysis
[3]

None
[0]

Chronic hepatitis
[2]

Cirrhosis
[3]

1 stable condition
[2]

The presence of ANY:
Cancer (active treatment)
Bone marrow/organ transplantation
Immune deficiencies
Poorly controlled HIV/AIDS
Chronic steroid use
[3]

Cardiovascular

Obesity
Diabetes (A1C)
BGM (mg/dl)
(Consider finger-stick BGM if
A1C is not available)
Renal

Hepatic

High Risk

Immuno-compromised state
None
[0]

** The scoring number for risk factor is listed in parentheses. This number indicates the points for that condition.
Low Risk: <= 7 points Moderate Risk: 8‐14 points
High Risk:>=15 points
BGM = blood glucose meter; BMI = body mass index; CAD = coronary artery disease; CHF = congestive heart failure; COPD = chronic obstructive pulmonary disease; HTN = hypertension
Adapted with permission: Shah S, Diwan S, Soin A, et al. Evidence-informed risk mitigation and stratification during covid-19 for return to interventional pain practice: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician 2020; 23:S161-S182(3).

of the subject and ongoing evolutionary changes, an
evidence-informed strategy was utilized instead of
evidence-based strategy.
The evidence-based medicine process relies on
quantitative research studies that provide the highest
levels of evidence for decisions about interventions
and other aspects including diagnosis, side effects, and
prevalence (43). However, the evidence-based approach
is also considered too restrictive and that decisionmaking for individual patients, for an organization, for
a population, or on various subjects without substantial
evidence and evolving in epidemiology must rely on ad-
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ditional forms of evidence that are much more inclusive
and less rigid.
Woodbury and Kuhnke (43) proposed that information used to make clinical decisions in clinical
practice should include more than evidence collected
with a singular goal of reducing bias in interventional
research and should include a variety of sources of
research information that addresses a wider range of
goals. Thus, Estabrooks (44) suggested that clinicians
add their own conventional wisdom and common sense
in the form of knowledge gained from qualitative and
sometimes quantitative studies. Even though the term
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“evidence-informed” is used infrequently compared to
evidence-based, the distinction and advantages have
been clarified by Woodbury and Kuhnke (43). A further
nuance has been provided by, Miles and Loughlin (45)
who promoted using the term “evidence-informed”
to indicate that the process be person-centered rather
than focused on the signs of reducing the quantitative
evidence, which, they claim has taken humanity out
of clinical practice. Further, multiple international and
national organizations promote the idea of evidenceinformed decision-making, such as the World Health
Organization (WHO) refers to evidence-informed policymaking (46), while the Canadian Institute for Health
Research also refers to evidence-informed decision
making (47). Even though some utilize evidence-based
and evidence-informed interchangeably, more recently,
with a movement towards real world evidence, it appears that evidence-informed may be a more appropriate term with more flexibility regarding the nature of
the evidence and its use. Thus, it may be considered
that evidence-informed medicine extends beyond the
definition of evidence-based medicine with the inclusion of real world evidence in real-world settings.

2.4.1 Grading or Rating the Quality or Strength of
Evidence
The grading of evidence is based on randomized
controlled trials, observational studies, and other clini-

cal reports. In addition, systematic reviews and metaanalyses were utilized. The grading of evidence based
on ASIPP guidelines is shown in Table 2 (42).
This grading system specifies levels of scientific evidence and offers an approach to grading the quality of
evidence and secondarily the strength of recommendations. AHRQ has recommended a similar approach to
the strength of a recommendation (40,41).

2.4.2 Rating or Grading the Strength of
Recommendations
IOM standards demand that for each recommendation, a rating of the strength of the recommendation related to benefits and harms, available evidence,
and the confidence in the underlying evidence should
be provided. To meet appropriate standards, the rating schemes recommended by NEATS were utilized as
shown in Table 3 (40).

3.0 Results
All the relevant studies were identified by search
of multiple databases with the search focusing on
COVID-19 related elective surgery recommendations,
including the CDC and multiple states, epidemiology,
pathophysiology, complications, testing and guidance
on prevention in the perioperative period. There were
no manuscripts available describing specific evidencebased or evidence-informed guidance for triaging

Table 2. Qualitative modified approach to grading of evidence.
Strong

Evidence obtained from multiple relevant high-quality randomized controlled trials for effectiveness
or
Evidence obtained from multiple relevant high quality observational studies or large case series for
assessment of preventive measures, adverse consequences, and effectiveness of other measures

Moderate

Evidence obtained from at least one relevant high-quality randomized controlled trial or multiple relevant
moderate or low-quality randomized controlled trials
or
Evidence obtained from at least 2 high-quality relevant observational studies or large case series for
assessment of preventive measures, adverse consequences, and effectiveness of other measures.

Level III

Fair

Evidence obtained from at least one relevant high-quality nonrandomized trial or observational study with
multiple moderate or low-quality observational studies
or
At least one high-quality relevant observational studies or large case series for assessment of preventive
measures, adverse consequences, and effectiveness of other measures.

Level IV

Limited

Evidence obtained from multiple moderate or low-quality relevant observational studies
or
Evidence obtained from moderate quality observational studies or large case series for assessment of
preventive measures, adverse consequences, and effectiveness of other measures.

Level V

Consensus based

Opinion or consensus of large group of clinicians and/or scientists for effectiveness as well as to assess
preventive measures, adverse consequences, and effectiveness of other measures.

Level I

Level II

Modified from: Manchikanti et al. A modified approach to grading of evidence. Pain Physician 2014; 17:E319-E325 (84).
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Table 3. Guide for strength of recommendations.

Rating for Strength of Recommendation
Strong

There is high confidence that the recommendation reflects best practice. This is based on: a) strong evidence for a true net
effect (e.g., benefits exceed harms); b) consistent results, with no or minor exceptions; c) minor or no concerns about study
quality; and/or d) the extent the panelists’ agreement. Other compelling considerations (discussed in the guideline’s literature
review and analyses) may also warrant a strong recommendation.

Moderate

There is moderate confidence that the recommendation reflects best practice. This is based on: a) good evidence for a true
net effect (e.g. benefits exceed harms); b) consistent results, with minor and/or few exceptions; c) minor and/or few concerns
about study quality; and/or d) the extent of panelists’ agreement. Other compelling considerations (discussed in the guideline’s
literature review and analyses) may also warrant a moderate recommendation.

Weak

There is some confidence that the recommendation offers the best current guidance for practice. This is based on: a) limited
evidence for a true net effect (e.g., benefits exceed harms); b) consistent results, but with important exceptions; c) concerns
about study quality; and/or d) the extent of panelists’ agreement. Other considerations (discussed in the guideline’s literature
review and analyses) may also warrant a weak recommendation.

Source: National Guideline Clearinghouse Extent Adherence to Trustworthy Standards (NEATS) instrument (84).

interventional pain procedures during COVID-19 or
related elective surgery restrictions. However, related
to the complex nature of the problem, in a pandemic
setting with lockdowns and resurgence without much
guidance available, the present assessment was unable to apply evidence-based principles with grading
of evidence and the strength of recommendations as
described previously in ASIPP guidelines (44-47).
Consequently, our study has utilized an informed
approach including the consensus-based decision-making for evidence synthesis and consensus-based criteria
and provided recommendations based on all types of
evidence.

3.1 Impact of COVID-19 on Chronic Pain
Patients
The lack of specialists and limited procedures being
performed have meant that fewer patients are treated
or that formerly routine procedures such as a steroid
injections necessitate complicated clinical logistics and
may arouse tremendous anxiety in patients (33). Telehealth visits may be helpful for some high-functioning
patients with stable chronic pain (48). However, there
are no effective electronic alternatives to the interventional techniques or manual therapies that enable
some patients to perform their basic activities of daily
living (33). These patients are in particularly dire straits
because, with the shutdown and the emphasis on social
distancing, they cannot rely on others to help them obtain food or other necessities. Moreover, some patients,
such as those requiring regular refills of their intrathecal pumps, are at increased risk of sudden death from
the abrupt depletion and withdrawal of the medications in their pumps.
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3.2 Impact of Elective Surgery Restrictions on
Pain Patients
Chronic pain causes significant physical and emotional suffering, limits everyday activities, and markedly reduces the quality of life. People suffering from
subacute or chronic pain face challenges in getting
through their daily chores, work, and family responsibilities. IPM has emerged as a powerful tool to help address the symptomatic burden these people face when
conventional treatments, such as physical therapy,
chiropractic adjustments, pharmacotherapy, surgery
and even alternative treatment such as acupuncture
have been exhausted. The COVID-19 pandemic has put
a screeching halt to these adjuvants and restrictions related to social distancing have led to shutting down of
physical therapy centers, chiropractic clinics, and other
healthcare services.
Even maintaining a pharmacological regimen could
be challenging as many pain physicians were forced to
restrict their practices due to state-guided restrictions
and lack of support staff. With widespread school
closures, many clinical support personnel had to take
time off from work to care for their children. Moreover,
patients often canceled their regular appointments for
fear of exposure to the infection. Telemedicine and
eHealth approaches are being developed and tested in
a gradual fashion, there are still barriers to the acceptance and adoption of telehealth (27).
Physicians and other healthcare providers face
a myriad of problems related to caregiver services. In
two-parent households where both parents must work
outside the home (ex. married doctors), child care is
often an issue. Because daycare centers and schools
are closed, one parent may have to withdraw from the
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workforce. This problem is often magnified in singleparent and divorced parent households. In many situations, physicians and other healthcare providers are
caregivers for elderly or disabled parents living at home.
Some of these clinicians leave the workforce because
they cannot find adequate home health services due to
the shutdown. Single and divorced pet owners may also
face difficulties. The lack of caregiver services, due to a
combination of COVID and the shutdown, has resulted
in a decrease in the number of available healthcare
workers. Because medical care is often delivered by
teams rather than individuals (e.g., one physician, one
nurse, one medical assistant and one receptionist), the
absence of a team member creates an undue burden on
the rest of the team and can also translate to inefficiencies in patient care whether virtual or face-to-face.
Further, people working virtually from home also
experienced repetitive strain injuries related to poor
ergonomics and the lack of appropriate workstations
at home.
As indoor family time has increased with the
pandemic, more people have suffered acute exacerbations of their chronic spinal conditions or suffered
new injuries to the spine attempting to fix their cars,
houses, increasing indoor or outdoor exercise routines,
or simply playing with their children. Unable to obtain
appointments with their primary care doctors, physical
therapists, or chiropractors and shutting of urgent care
centers or emergency departments, these patients had
to manage their new or exacerbated painful conditions
with little support. Telemedicine platforms and radiological scans could be helpful in identifying the underlying cause of pain in many such clinical situations, but
treatment options were limited. Conservative courses
of treatment, such as physical therapy, were often precluded. Pharmacological therapy became an important
option, but the new or ongoing use of NSAIDs, steroids,
and opioids (and possibly at higher doses) has also been
a matter of concern. More recent studies have shown
an increase in substance abuse, opioid and non-opioid
overdoses during the COVID pandemic (49-58). In addition, multiple aspects of psychosocial impact of COVID-19 (59) with potential implications for individuals
with substance use disorders (60-65). In fact, Becker and
Fiellin (63) described coalition effect of COVID-19 and
the opioid crisis. The effects also entered into social dynamics with descriptions of how fighting one pandemic
can deepen another one described as deaths of despair
with increasing deaths and mortality in mid-life among
white non-Hispanic Americans in the 21st century (66).
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Oncology patients were particularly hard hit, as
there were no clear guidelines on safe and appropriate care (35). Cancer patients appear to be at elevated
risk for severe and even critical responses to COVID-19,
particularly those who were undergoing or recently
completed chemotherapy. Cancer patients, being at
high risk for potentially life-threatening COVID-19
infections, are often discouraged from travelling to
receive care.
It is well known that IPM is an effective and valuable option for many patients experiencing sudden
exacerbations in pain. Interventional options in many
cases may improve function and eliminate or reduce
the need for opioids (67). Opioids (68), uncontrolled
pain (69), and steroids (5,70-75) can all suppress the
immune system. IPM with local anesthetics or reduced
or steroids (3,5,70-75) would be considered “an alternative.” A clear stratification of specific IPM techniques as
we propose along with a cautious approach to deliver
these modalities at all levels, i.e., office-based practices,
ambulatory surgery centers, and hospitals, would serve
our specialty and our patients better in the future.

3.3 Impact of Elective Surgery Restrictions
on IPM Practices
Almost every doctor treats pain in some form. IPM
physicians are called to treat some of the most challenging painful conditions when conservative treatment modalities have been exhausted and surgical
options are either not applicable or not recommended.
The initial ban on elective surgery combined with the
nationwide “lockdown” and other pandemic-related
restrictions had serious consequences for chronic pain
practices. There is a misperception in the medical community and by some ambulatory surgery centers (ASCs)
and hospital administrators that “most” IPM services are
elective. As a result, across the country, some hospitals
and ambulatory care centers closed their IPM services
under the justifications that they are purely elective.
Often, in these settings, interventional pain physicians
or their representatives were not part of the discussion.
As a result, some chronic pain patients who had come
to rely on regular IPM care practices for their basic function found that their care was not available. Since the
COVID-19 pandemic and related societal shutdowns
encompassed many unknown variables—such as how
long it would last and how severe it would get—pain
patients struggled and braced themselves for dealing
with untreated and otherwise untreatable pain for an
indeterminate amount of time. Many worried about
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the long-term effects of untreated pain beyond their
present suffering and on their ability to attend to basic
needs such as self-care, food shopping and preparation,
family care, caring for their loved ones, household duties, work duties, and their other medical conditions.
IPM physicians found navigating their patients’
treatment through the healthcare system challenging
while COVID-19 outbreak related restrictions were
in effect. Only one third of IPM physicians work in an
office-based setting, but a large proportion of providers perform their procedures in a hospital suite or ASCs
(14). Even office-based proceduralists must utilize hospitals or ASCs for certain cases due to various medical or
non-medical reasons. CMS elective surgery restrictions
essentially resulted in decimation of IPM services nationally at hospitals and ASCs.
The same challenges were faced by hospitals and
ambulatory care centers, all of which had to adapt
their practice models in order to keep up-to-date with
regulations, official guidance, and the vagaries of
supply-and-demand as the nation’s healthcare system
struggled to allocate limited resources efficiently. One
particularly hard-hit aspect of traditional care was the
postoperative visit, which was largely dispensed with.
Frontline clinicians made heroic efforts to navigate this
unprecedented new medical landscape in a way that
optimized safety and administered important treatments as much as possible. However, there is no doubt
that during the pandemic many IPM patients may not
have received optimal care because of COVID-19-related restrictions and concerns. Based on these simple
facts, several key interventional procedures in subacute
severe pain settings should be placed at a higher tier
on the American College of Surgeons Elective Surgery
Acuity Scale (ESAS) (37).

3.4 IPM Resource Utilization
When an interventional procedure is being considered for a pain patient, the clinical team must first
evaluate not only the patient’s relevant medical condition but his or her history with respect to COVID-19,
including antigen or antibody testing and/or chest x-ray
as deemed clinically appropriate by the ASIPP risk stratification table (3). Additionally, all the procedures must
be performed within the framework of federal, state,
and local regulations. Adequate PPE must be available
for all in proximity to the patient. Note that in procedures in which the patient may be intubated or extubated, there is a strong probability of aerosolization.
If general anesthesia is required, it should be induced
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and the patient intubated by an experienced healthcare professional; intubation should be carried out using rapid-sequence induction with video-laryngoscopy
and minimal use of bag-mask ventilation. After general
anesthesia, the patient should be extubated using airborne PPE. Following surgery, the patient should wear
a surgical mask and receive high-flow oxygen (~6L/min)
to reduce the risk of aerosolization.
Regional anesthesia is not considered to cause a
high degree of aerosolization, so droplet precautions
need not be as stringent with this type of anesthesia. If
regional anesthesia is utilized, all precautions should be
taken to help minimize the risk of emergency conversion to general anesthesia during the procedure (34).
Ultrasound may be used for guidance of peripheral
nerve blocks but care should be taken to shield the
equipment with disposable coverings (34).
During any procedure carried out in the COVID-19
era, it is important to minimize the presence of equipment in the room and protect what remains as much
as possible with disposable coverings. While adequate
clinical staff is needed, the fewer people involved the
better; all personnel should wear appropriate PPE
throughout the entire procedure (34).
Special care should be taken in moving the patient
to and from the procedure. In some cases, the patient
may need to recover in an airborne-infection isolation
area (34).

3.5 Definition of Medical Urgency of a Case
In the context of IPM, medical urgency can be stratified by individual’s clinical circumstances and by case.
Certain types of cases can be safely postponed for a
short duration and some may be postponed indefinitely
with no harm to the patient. However, postponing
other types of IPM procedures may subject the patient
to risks, such as unrelieved pain, severe functional decline, the need to rely upon pharmacotherapy with its
attendant risks, or the need to increase doses of opioids
or NSAIDs. In many cases, there is an interplay of factors
such that risks compete —the risk of exposure to viral
infection versus the risk of untreated pain versus the
risk of higher-than-usual drug doses.
Acute pain may be a symptom of a significant underlying disease and may be addressed as an emergency.
In patients with subacute or chronic painful conditions,
pain and concomitant severe functional limitations in
addition to failure to manage it appropriately is associated with risks and may harm the patient. Patients
with unrelieved chronic pain may be at risk for a host
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of other conditions such as memory loss (76), dementia (76), attention (77), depression (78,79), functional
deficits (79), anxiety (80), insomnia (81), suicidality (82),
and others. Unrelieved chronic pain has been associated with early mortality (83). Poorly treated acute and
chronic pain may lead to imprinting in the peripheral
and central nervous system (84,85).
Chronic pain in progressive diseases may be a
symptom of a worsening underlying condition. Not
only should this pain be treated, but it should also be
regarded as a potential warning symptom that the
disease may be getting worse or complications may be
developing. For that reason, pain in progressive conditions should be closely monitored. Furthermore, the
pain in patients at end of life can be severe, unremitting, and deserves adequate control (86).
In the COVID-19 area, the need to protect the
patient from viral exposure must be weighed against
the need for pain care. Numerous strategies have been
proposed to mitigate the risk of viral transmission in
the clinical setting, including PPE for clinicians, masks
for patients, social distancing, hand hygiene, and so
on. The risks of unrelieved moderate to severe pain are
more challenging to reduce and reduction strategies,
such as drug therapy or higher doses of drugs, carry
with them risks that must be evaluated on a case-bycase basis. In some cases, postponing an IPM procedure
may worsen the condition and may result in transforming a routine procedure today into a surgery or an
emergency procedure next week.
Opioids may be prescribed to reduce pain in patients who must delay a needed IPM procedure. This
is not an optimal strategy in that there are numerous
opioid-associated function limiting side effects including drowsiness, somnolence, dizziness, pruritus, mental
fog or confusion, constipation, headache, nausea, and
others (87). These side effects can even be treatment
limiting (88). While some symptoms will remit over
time as tolerance develops, other symptoms such as
opioid-induced constipation often persist throughout
the duration of therapy (89). Beyond those adverse effects, there is a potential risk that the long-term use
of opioids may result in opioid dependence and even
opioid use disorder (90). There are established risk factors for opioid use disorder, such that certain patients
must be regarded as being at elevated risk and possibly
as inappropriate candidates for opioid treatment (91).
While delayed IPM procedures may be managed safely
in some patients with short-term or even long-term opioid therapy, this is not the optimal course of treatment

S194

for interventional pain patients and may be associated
with serious safety concerns for certain patients.

3.6 IPM Acuity Scale
While nothing can replace clinical judgment for
an individual case, the creation of an acuity or ranking
scale may serve as a valuable tool for objective classification of patients to determine the need for IPM.
Acuity scales can be crucial in helping to triage patients
when resources are scarce and an orderly system is
needed to assure all patients get appropriate care in as
efficient a manner as possible (92). The determination
as to whether a procedure is emergently or urgently
indicated cannot be based solely on whether or not
the procedure might be described as “elective” (93).
The medical necessity for a procedure should be determined by an interventional pain specialist and may
take multiple factors into account. Some factors include
the patient’s pain severity, physical incapacitation, underlying condition, comorbidities, disease progression,
mental health status, response to alternative treatments, visits to other healthcare professionals, extent
of analgesic management including the use of opioids
and likely outcomes if the procedure is performed or
delayed (93). Logistics and community safety may also
play a role as healthcare resources may be limited (93).
Blanket decisions on procedures should be avoided, as
this is a dynamic environment with stark differences
among regions and types of pain patients and their
related functional impairments and differences in regional regulations.
For patients undergoing treatment at an ambulatory care center or other outpatient facilities, the
CDC recommends that patients be contacted prior to
visiting the center to be screened by phone for risk
of COVID-19; following surgery, telephone follow-up
can check on patients, verify medication adherence,
and respond to questions the patients may have. If a
person with known or suspected COVID-19 must be
treated face-to-face, the patient should be asked to call
before arriving at the facility so that the staff can be
prepared (PPE, infection control practices) and so that
the patient can be moved quickly into the system and
receive care promptly. If patients or those accompanying them must wait in a waiting room, assure adequate
distance between seats (six feet) and mark waiting lines
to prevent patients from clustering together. In some
cases, family and friends accompanying patients may
have to be asked to wait outside. The CDC recommends
that medical facilities waive any penalties they might
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Table 4. ASIPP guidance for triaging pain interventions with examples.

Description
1

Emergent

Intermediate acuity
Unable to perform essential
ADLs

Locations
Office-based
Outpatient
ASC
Inpatient

Progressive pain despite
conservative treatment

Examples
Failed noninterventional
management
New onset or exacerbation
of CRPS.
Acute exacerbation of
radiculopathy
Degenerative or neurological
disease with walking
difficulty

Possible future morbidity
Exacerbation of underlying
medical condition or may
proceed to surgery if not
treated with pain intervention
Psychosocial implications
Escalating opioid doses
Risk of chemical coping

Intervention
Examples
Epidural injections
Lumbar sympathetic
block
Epidural catheter in
cancer pain
Stellate ganglion block

Perform
procedure after
reasonable efforts
to postpone with
alternatives.
Physician’s
discretion.

Epidural blood patch

Degenerative or neurological
disease with painful use of
upper extremities

Intercostal nerve blocks

Intervention performed to
provide pain relief to allow
conservative management
such as physical therapy

Facet joint interventions

Thoracic nerve blocks for rib
fractures

Timing

Vertebral augmentations

Peripheral nerve blocks
pump refills
Other interventionsl

PDPH
2

Urgent

Severe acuity
Unable to perform most
ADLs due to severe physical
incapacitation
Rapidly progressive pain
Rapidly progressive decline in
function
Repeated ED visits due to pain
High probability of future
morbidity if procedure not
performed
Exacerbation of underlying
medical condition or may
proceed to surgery if not
treated with interventional pain

Office-based
Outpatient
ASC
Inpatient

Impending severe drug
withdrawal
Disabling CRPS
Degenerative or neurological
disease with severe walking
inability

Pump refills

Do not postpone

Epidural injections
Facet joint interventions
Peripheral nerve blocks

Intercostal nerve blocks
Degenerative or neurological
disease with severe inability to Vertebral augmentation
use upper extremities
Lumbar sympathetic
Alternative to pending spine
block
surgery, if appropriate
or
Stellate ganglion block
Any
severe
debilitating
disease that prevents patients Other interventions
from performing activities of
daily living.

Development of an
unacceptable medical condition
unless the procedure is
performed
Pharmacologically and
otherwise unmanageable pain
Substantial risk of psychosocial
harm
Substantial risk of opioid
misuse, abuse and chemical
coping
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Table 4 (connt.). ASIPP guidance for triaging pain interventions with examples.

Description
3

Elective

Low acuity

Locations
Office-based
Outpatient
ASC
Inpatient

Healthy patient
Stable

Examples

Intervention
Examples

Any pain condition that is Any procedure
stable and can be managed
with alternatives

Timing
P o s t p o n e
procedure until
elective surgery
ban lifted

Able to perform ADL
No meaningful
limitation

functional

Low risk to patient
Low-risk options available
(home
physical
therapy,
pharmacological therapy)

normally impose on patients who miss appointments
as patients may suddenly develop symptoms such that
staying home is the appropriate and safe choice.
An acuity scale based on that modeled by the ESAS
(94) was developed by the authors and appears as Table
4. It is important to keep in mind that although there
is a tier classification, individuals often present to the
pain clinician over a continuum.

4.0 Relevance

to

Clinical Practice

The use of ASIPP’s IPM acuity classification will aid
in the rapid, objective assessment of acute and chronic
pain patients during the gradual phased re-opening
following the COVID-19 shutdown and prepare the IPM
specialty for “second waves”, repeat shutdowns, future
pandemics and many other similar meltdowns similar
to what occurred during the COVID-19 pandemic.
It must be stressed that an acuity scale is only a tool
and constitutes many elements of a large mosaic that
considers the patient holistically, that is, the patient’s
overall condition, including daily function, pharmacological drug use, comorbidities, risk factors, mental
health, social risk factors and prognosis. Careful and
consistent documentation is needed when reaching
decisions about IPM triage. In this context, the use of
templated tools can be helpful as it both accelerates
and streamlines documentation to facilitate functional
patient care without sacrificing accuracy.
Elective care describes those procedures that can
safely and reasonably be postponed with little to no
harm to the patient or in cases where performing the
procedure would pose greater risk to the patient in
terms of viral exposure than the delay of the inter-
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ventional pain procedure. Emergent and urgent acuity classification for IPM patients is appropriate and
may be carried out when the clinician assesses that a
delay would result in unacceptable disease progression, intractable pain, disability, or suffering. Emergent
and urgent cases can be performed when there is an
assessment that delay would result in either unacceptable progression of disease, intractable pain, disability,
or suffering. Optimally, the procedure should be performed under local anesthesia to conserve resources
and minimize the chance of airway manipulation and
super-spreading events that may ensue.

5.0 Discussion
As the American health care system returns to
pre-COVID practice, the focus must be on providing
health care services in a strategic manner, including
to those patients suffering with chronic pain, using
evidence-based methodologies in these and other relevant, reputable guidelines. ASIPP has developed risk
stratification (3) based on patient comorbidities and
this must be carried out to achieve optimal outcomes,
moving forward, either during Phase I, II, or III or during
resurgence with repeat of some of the phases. As usual,
physician discretion, shared decision-making, following
all the appropriate precautions including testing, with
use of proper anesthetic techniques, is crucial, not only
for quality, but also for patient safety and the safety of
the physicians and other health care staff.
Although patients may challenge the risk assessment and stratification strategies to be undergone
prior to procedures, the due attention will also provide
comfort to patients that we are providing evidence-

www.painphysicianjournal.com

Guidelines for Triaging Interventional Pain Procedures During COVID-19

based or evidence-informed care. However, patients
may also feel disappointment, when the indicated
procedure is denied because their pain intervention
belongs to a different category than surgical procedures. Consequently, it is crucial to provide the patient
with appropriate informed consent, both to provide a
good outline of key points in the risk assessment, to
provide patients with take home material to review at
their leisure, and to serve as clinical documentation. To
a great extent, information provided, specifically based
on evidence, and guidance, dispels confusion, reduces
fear, and helps to improve not only the quality of care,
but also patient satisfaction.
There are multiple limitations to the present
guidelines. As we have seen, there is not a high level
of evidence based on randomized controlled trials.
Consequently, we utilized evidence informed decision
making, which is practical and fits today’s practices of
real-world medicine. These recommendations were
made during Phase II and III of re-opening, but by the
writing of this manuscript, significant resurgence has
been noted in multiple states, with Texas already stopping the elective surgical procedures.

6.0 Conclusion
The COVID-19 pandemic has created unprecedented challenges in IPM that need not culminate
in unnecessary suffering for pain patients. As facilities
and society gradually re-open, a triage system based on
an acuity metric is needed for the appropriate care of
patients based on their clinical need, safety, and status oflocal healthcare facilities. Many IPM procedures
cannot be indefinitely postponed, although it is often
possible to briefly delay a procedure without adverse
consequences. Chronic pain exacerbations are associated with marked functional declines and treatment risks
of alternative treatment modalities must be considered
with the concern that they deserve. Clinicians must holistically assess patients, local healthcare resources, and
weigh the benefits and risks of a procedure against the
risks of exposure to the COVID-19 virus at all times.
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